distinguish
advers
event
relat
ribavirin
therapi
attribut
sever
acut
respiratori
syndrom
sar
determin
rate
potenti
ribavirinrel
advers
event
design
retrospect
cohort
studi
set
hospit
toronto
ontario
canada
patient
cohort
patient
confirm
probabl
sar
receiv
ribavirin
februari
juli
treat
patient
receiv
highdos
ribavirin
treat
patient
receiv
lowerdos
regimen
measur
main
result
data
patient
sar
admit
hospit
toronto
abstract
chart
electron
databas
onto
standard
form
train
research
nurs
logist
regress
use
evalu
associ
ribavirin
use
advers
event
progress
anemia
hypomagnesemia
hypocalcemia
bradycardia
transamin
hyperamylasemia
adjust
sarsrel
prognost
factor
corticosteroid
use
primari
logist
regress
analysi
ribavirin
use
strongli
associ
anemia
odd
ratio
confid
interv
ci
p
hypomagnesemia
ci
p
bradycardia
ci
hypocalcemia
transamin
hyperamylasemia
associ
ribavirin
use
risk
anemia
hypomagnesemia
bradycardia
attribut
ribavirin
use
respect
conclus
highdos
ribavirin
associ
high
rate
advers
event
use
highdos
ribavirin
appropri
treatment
infecti
diseas
ribavirin
proven
clinic
efficaci
context
clinic
trial
ribavirin
use
empir
treatment
viral
syndrom
unknown
origin
ribavirin
synthet
purin
nucleotid
analog
vitro
activ
wide
rang
rna
dna
virus
chronic
hepat
c
combin
sever
respiratori
syncyti
viru
pneumon
viral
hemorrhag
fever
particularli
lassa
fever
mechan
action
fulli
understood
ribavirin
use
empir
earli
outbreak
sever
acut
respiratori
syndrom
sar
broadspectrum
antivir
activ
toronto
ontario
canada
patient
seen
initi
phase
outbreak
treat
highdos
intraven
ribavirin
base
protocol
recommend
treatment
hemorrhag
fever
howev
initi
vitro
studi
ribavirin
suggest
inhibit
viral
replic
would
possibl
clinic
achiev
dose
studi
clinic
efficaci
ribavirin
patient
sar
inconclus
signific
advers
event
report
includ
sever
hemolysi
result
first
phase
outbreak
end
clinician
toronto
stop
use
ribavirin
unlik
citi
toronto
sar
outbreak
biphas
larg
cluster
case
occur
use
ribavirin
discontinu
toronto
outbreak
uniqu
signific
number
patient
treat
treat
ribavirin
provid
opportun
distinguish
ribavirininduc
advers
event
advers
event
directli
attribut
sar
estim
frequenc
sar
advers
event
larg
group
patient
treat
highdos
ribavirin
retrospect
cohort
studi
captur
data
advers
event
adult
patient
age
yr
confirm
probabl
sar
admit
hospit
toronto
sar
outbreak
februari
juli
patient
consid
probabl
sar
compat
clinic
ill
fever
nonproduct
cough
dyspnea
exposur
sar
direct
contact
patient
known
sar
case
travel
sarsendem
area
time
spent
institut
sar
transmiss
occur
within
day
symptom
onset
infiltr
chest
radiograph
patient
consid
confirm
sar
compat
clinic
ill
exposur
sar
posit
microbiolog
test
posit
acut
convalesc
serolog
posit
polymeras
chain
reaction
sar
coronaviru
clinic
patholog
specimen
serolog
microbiolog
method
use
describ
previous
definit
ribavirin
exposur
primari
secondari
outcom
ribavirin
use
exposur
interest
patient
consid
expos
receiv
least
one
dose
ribavirin
onset
advers
event
patient
consid
expos
receiv
ribavirin
onset
outcom
primari
outcom
examin
advers
event
ribavirin
defin
appendix
progress
anemia
hypomagnesemia
hypocalcemia
bradycardia
transamin
hyperamylasemia
outcom
select
either
known
ribavirininduc
advers
event
consid
possibl
ribavirininduc
advers
event
base
data
noncontrol
studi
ribavirintr
patient
sar
appendix
could
defin
use
clinic
laboratori
paramet
measur
routin
treat
nontreat
patient
secondari
outcom
interest
evid
hemolysi
clinic
signific
symptomat
bradycardia
tetani
muscl
spasm
hepat
pancreat
appendix
data
abstract
chart
electron
databas
onto
standard
form
train
research
nurs
data
doubl
enter
access
databas
microsoft
corp
redmond
wa
studi
approv
research
ethic
board
particip
hospit
mcmaster
univers
hamilton
ontario
univers
toronto
toronto
ontario
canada
analysi
conduct
use
sa
softwar
version
sa
institut
cari
nc
univari
analys
continu
variabl
compar
use
wilcoxon
rank
sum
test
twosampl
test
appropri
categor
variabl
compar
use
fisher
exact
test
appropri
attribut
risk
advers
event
determin
subtract
rate
advers
event
nontreat
patient
rate
treat
patient
check
presenc
doserespons
effect
reclassifi
exposur
high
dose
high
dose
ribavirin
receiv
regimen
consist
intraven
load
dose
follow
g
intraven
everi
hour
day
follow
mg
intraven
everi
hour
day
consid
highdos
treatment
regimen
consid
highdos
treatment
proport
highdosetr
highdosetr
nontreat
patient
outcom
examin
graphic
cochranearmitag
trend
test
primari
analysi
multivari
logist
regress
analysi
examin
associ
ribavirin
use
advers
event
adjust
factor
predict
sever
sar
corticosteroid
use
predictor
includ
model
age
comorbid
oxygen
satur
chest
radiograph
find
absolut
neutrophil
count
lactat
dehydrogenas
level
measur
admiss
factor
associ
progress
respiratori
failur
need
mechan
ventil
death
sar
multipl
imput
use
imput
miss
valu
predict
factor
model
approach
shown
power
less
bias
exclud
analysi
patient
one
miss
predictor
test
five
hypothes
primari
analysi
ie
associ
ribavirin
five
advers
event
maintain
use
bonferroni
correct
lower
p
valu
threshold
statist
signific
confid
interv
ci
also
adjust
approach
minim
risk
identifi
chanc
associ
due
multiplehypothes
test
cohort
consist
patient
confirm
patient
probabl
patient
sar
ribavirin
given
patient
use
equival
confirm
versu
probabl
case
vs
first
phase
outbreak
patient
receiv
ribavirin
second
phase
patient
receiv
ribavirin
corticosteroid
therapi
specif
therapi
sar
wide
use
outbreak
overal
patient
receiv
treatment
receiv
ribavirin
receiv
corticosteroid
receiv
ribavirin
start
promptli
patient
receiv
first
dose
within
hour
admiss
mean
sd
total
dose
receiv
g
median
durat
treatment
day
interquartil
rang
iqr
day
full
treatment
cours
complet
patient
reason
discontinu
among
patient
complet
cours
therapi
includ
advers
event
attribut
treatment
patient
clinic
improv
death
chang
treatment
guidelin
patient
refus
reason
document
advers
event
document
caus
drug
discontinu
includ
anemia
hemolysi
patient
druginduc
hepat
transamin
bradycardia
atrial
fibril
nausea
unspecifi
overal
treat
patient
receiv
highdos
ribavirin
treat
patient
receiv
varieti
lowerdos
regimen
mean
total
dose
receiv
g
highdos
group
g
lowerdos
group
rate
discontinu
similar
group
vs
baselin
characterist
ribavirintr
nontreat
patient
shown
tabl
ribavirintr
patient
like
hypoxem
vs
higher
baselin
lactat
dehydrogenas
level
vs
ul
p
lower
absolut
neutrophil
count
vs
median
age
similar
group
vs
yr
outcom
similar
group
term
need
mechan
ventil
vs
case
fatal
rate
vs
univari
analysi
advers
event
occur
often
ribavirintr
patient
strongest
associ
seen
progress
anemia
hypomagnesemia
tabl
figur
bradycardia
hypocalcemia
also
significantli
common
among
ribavirintr
patient
ribavirin
use
statist
significantli
associ
transamin
hyperamylasemia
progress
anemia
hypomagnesemia
graphic
evid
doserespons
effect
figur
primari
adjust
analysi
ribavirin
remain
strongli
associ
hypomagnesemia
odd
ratio
ci
p
progress
anemia
ci
p
tabl
modest
associ
also
persist
bradycardia
ci
ribavirin
appear
significantli
associ
hypocalcemia
ci
transamin
ci
primari
analysi
hyperamylasemia
examin
insuffici
number
allow
meaning
multivari
analysi
frequenc
time
clinic
signific
advers
event
associ
ribavirin
use
ribavirin
use
associ
hypocalcemia
transamin
appear
sarsrel
effect
therefor
focus
frequenc
time
clinic
signific
ribavirininduc
anemia
hypomagnesemia
bradycardia
progress
anemia
occur
ribavirintr
patient
hemolysi
confirm
patient
progress
anemia
occur
nontreat
patient
risk
anemia
attribut
ribavirin
use
despit
higher
frequenc
progress
anemia
among
ribavirintr
patient
need
blood
transfus
similar
treat
versu
nontreat
patient
vs
mean
sd
decreas
hemoglobin
level
gdl
among
treat
patient
gdl
among
nontreat
patient
p
median
time
initi
treatment
develop
progress
anemia
day
iqr
day
hypomagnesemia
occur
treat
patient
nontreat
patient
attribut
risk
mean
sd
decreas
magnesium
level
among
treat
patient
meql
median
time
initi
treatment
occurr
hypomagnesemia
day
iqr
day
tetani
occur
treat
patient
nontreat
patient
patient
tetani
evid
electrolyt
imbal
hospit
hypocalcemia
bradycardia
occur
ribavirintr
patient
nontreat
patient
attribut
risk
bradycardia
consid
clinic
signific
bradycard
patient
median
time
initi
treatment
bradycardia
day
iqr
day
although
highdos
ribavirin
recommend
treatment
lassa
fever
may
use
hemorrhag
fever
syndrom
data
advers
event
associ
oral
parenter
ribavirin
come
studi
lower
dose
oral
ribavirin
use
treatment
chronic
hepat
c
report
frequenc
advers
event
patient
treat
highdos
ribavirin
toronto
sar
outbreak
although
studi
examin
ribavirinrel
advers
event
treat
patient
sar
publish
noncontrol
small
control
group
ie
seven
patient
knowledg
studi
first
studi
control
group
larg
enough
allow
differenti
ribavirinrel
advers
event
manifest
sar
result
confirm
progress
hemolyt
anemia
common
advers
event
highdos
ribavirin
although
progress
anemia
occur
among
nontreat
patient
presum
due
sar
sever
ill
effect
hospit
clinic
import
declin
hemoglobin
level
far
common
patient
treat
ribavirin
find
patient
develop
progress
anemia
larg
associ
hemolysi
substanti
higher
rate
seen
ribavirintr
patient
hepat
c
consist
report
previou
noncontrol
studi
ribavirinrel
advers
event
patient
sar
result
mislead
howev
given
nontreat
patient
cohort
also
develop
anemia
rate
excess
case
anemia
ie
attribut
risk
accur
estim
impact
ribavirin
therapi
although
may
still
overestim
given
nontreat
group
appear
milder
sar
treat
group
would
expect
less
sarsrel
anemia
despit
previou
studi
suggest
ribavirintr
patient
requir
blood
transfus
data
demonstr
higher
transfus
requir
treat
group
sar
outbreak
hypocalcemia
hypomagnesemia
recogn
advers
effect
ribavirin
howev
two
earli
case
seri
sar
case
toronto
suggest
hypocalcemia
hypomagnesemia
common
patient
sar
may
due
ribavirin
first
report
ribavirintr
patient
develop
tetani
associ
sever
hypomagnesemia
magnesium
level
meql
hypocalcemia
correct
calcium
level
mgdl
second
report
ribavirintr
patient
develop
hypomagnesemia
develop
hypocalcemia
studi
hypomagnesemia
hypocalcemia
relat
dose
ribavirin
receiv
larger
studi
first
phase
toronto
outbreak
demonstr
hypocalcemia
hypomagnesemia
occur
patient
respect
hospit
note
hypocalcemia
admiss
studi
hong
kong
china
singapor
taiwan
comment
hypocalcemia
hypomagnesemia
associ
ribavirin
use
although
much
lower
dose
ribavirin
use
area
result
clarifi
find
first
demonstr
hypomagnesemia
strongli
associ
use
highdos
ribavirin
diseaserel
effect
associ
dramat
less
nontreat
patient
develop
hypomagnesemia
compar
treat
patient
furthermor
estim
primari
adjust
analysi
ci
effect
appear
dose
depend
result
consist
find
previou
studi
studi
howev
suggest
hypocalcemia
diseaserel
effect
caus
ribavirin
hypocalcemia
occur
frequent
nontreat
patient
dose
depend
statist
significantli
associ
ribavirin
treatment
primari
adjust
analysi
result
also
consist
previou
studi
effect
appear
dose
depend
frequent
present
initi
ribavirin
therapi
furthermor
hypocalcemia
known
associ
sepsi
critic
ill
although
identifi
seven
case
tetani
associ
hypocalcemia
andor
hypomagnesemia
occur
approxim
equal
frequenc
ribavirintr
nontreat
group
although
associ
electrolyt
disturb
remain
unclear
role
ribavirin
play
advers
event
cardiovascular
effect
particularli
bradycardia
associ
ribavirin
use
analys
bradycardia
associ
ribavirin
use
univari
multivari
analysi
although
doserespons
effect
seen
bradycardia
clinic
signific
one
third
case
transamin
appear
sarsrel
effect
rather
ribavirin
effect
statist
significantli
associ
ribavirin
use
either
univari
primari
multivari
analys
find
consist
case
seri
describ
histolog
chang
liver
consist
coronavirusinduc
hepat
druginduc
hepat
final
trend
toward
higher
amylas
level
among
ribavirintr
patient
patient
elev
level
allow
multivari
analysi
patient
clinic
defin
pancreat
although
result
rule
pancreat
uncommon
advers
effect
highdos
ribavirin
therapi
pancreat
occur
cohort
studi
sever
limit
data
collect
retrospect
potenti
sever
type
bia
exist
clinician
awar
potenti
ribavirin
advers
event
may
test
record
event
frequent
ribavirintr
patient
similarli
data
abstractor
may
search
dilig
advers
event
ribavirintr
patient
addit
patient
sever
sar
like
treat
diseaserel
effect
would
appear
associ
treatment
select
bia
attempt
minim
bias
use
studi
end
point
object
measur
routin
treat
nontreat
patient
thu
anemia
consid
primari
outcom
rather
hemolysi
could
defin
base
hemoglobin
level
routin
measur
patient
oppos
haptoglobin
level
order
primarili
ribavirintr
patient
control
select
bia
use
logist
regress
adjust
factor
predict
sever
sar
although
approach
remov
bia
inher
retrospect
studi
result
repres
improv
previou
report
advers
event
patient
treat
highdos
ribavirin
examin
small
number
patient
andor
fail
includ
control
group
adjust
confound
factor
studi
result
confirm
highdos
ribavirin
caus
hemolyt
anemia
bradycardia
demonstr
first
time
knowledg
strike
associ
highdos
ribavirin
use
hypomagnesemia
previou
studi
suggest
patient
hepat
c
receiv
ribavirin
discontinu
treatment
due
cardiovascular
respiratori
effect
secondari
sever
anemia
includ
cardiac
respiratori
outcom
studi
primarili
cardiac
event
rare
report
cohort
potenti
respiratori
effect
ribavirin
imposs
distinguish
primari
manifest
sar
thu
clinic
impact
effect
remain
uncertain
although
clinic
marker
includ
surviv
transfus
requir
tetani
common
among
ribavirintr
patient
howev
cohort
larg
made
young
previous
healthi
health
care
worker
cohort
comorbid
ill
histori
cardiac
respiratori
diseas
older
cohort
comorbid
impact
ribavirinassoci
hemolyt
anemia
may
sever
ribavirin
dose
use
sar
toronto
boundari
appear
maximum
clinic
toler
dose
given
clear
associ
highdos
ribavirin
sever
potenti
sever
advers
event
high
frequenc
event
sever
recommend
appear
appropri
highdos
oral
parenter
ribavirin
use
monitor
set
patient
without
cardiac
respiratori
condit
would
exacerb
acut
declin
hemoglobin
level
previou
recommend
highdos
oral
ribavirin
provid
event
mass
casualti
situat
relat
natur
outbreak
unknown
hemorrhag
fever
syndrom
deliber
bioterrorist
attack
reassess
given
data
furthermor
use
ribavirin
outsid
clinic
trial
restrict
treatment
lifethreaten
condit
ribavirin
demonstr
improv
outcom
event
anoth
sar
outbreak
widespread
use
ribavirin
appear
justifi
given
equivoc
vitro
vivo
evid
efficaci
clear
evid
toxic
outbreak
occur
due
novel
viral
pathogen
believ
earli
use
highdos
ribavirin
even
context
control
clinic
trial
justifi
viru
isol
vitro
test
demonstr
ribavirin
activ
clinic
achiev
dose
natur
histori
ill
suggest
potenti
benefit
ribavirin
outweigh
harm
